Brunswick company making scientific advances toward more effective prescriptions at lower costs

BRUNSWICK, Maine — The side effects of any new pharmaceutical drug can often be scarier than what they’re meant to treat; but how can drug companies do better testing?

They can start with a company called InSphero. Armand Wolf, the Chief Scientific Officer for the company, spent years working in drug development in the pharmaceutical field.

“Most of the drugs, when they’re just reaching clinical phase, 90% of them are failing,” says Wolf. Those drugs are failing – on average – 10 years into testing. “It will cost about $1-2 Billion, so this is a huge waste of money.” Read more

Related Posts

Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research

The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...

22 August 2024

Bigelow lab receives $7 million for algae research, business development

Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...

21 August 2024

Should Maine create a public medical school? UMaine System will study the question

The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...

21 August 2024